Benicar is a medication made by Daiichi Sankyo that is taken to control high blood pressure. It has been linked to a gastrointestinal tract problem that leads to severe, chronic diarrhea with substantial weight loss. The GI tract problem is known as “sprue-like enteropathy.” It may develop months to years after you start to take Benicar. Sometimes, it requires hospitalization.
The medication in Benicar, which requires a prescription, is also sold as Benicar HCT, Azor and Tribenzor and in generic form. In July 2013 – long after Benicar entered the market – the U.S. Food and Drug Administration (FDA) approved changes to the labels of these drugs to warn consumers of the potential to develop entropathy after taking the medication.
If you believe that you have suffered harm from taking Benicar, you please contact Techmeier Law Firm in Milwaukee. We can provide a free and confidential review of your case.
GI Tract Problems and Benicar
The FDA describes Benicar (olmesartan medoxomil) as an angiotensin II receptor blocker (ARB). The FDA has approved the drug for the treatment of high blood pressure – either used alone or with other anti-hypertensive agents. It is one of eight marketed ARB drugs.
The problems that Benicar may cause resemble symptoms of celiac disease as well as sprue-like enteropathy. They include:
- Chronic diarrhea
- Rapid and excessive weight loss
- Cardiovascular problems.
Mayo Clinic researchers reported in June 2012 that the clinic had seen 22 olmesartan patients with symptoms that suggested celiac disease. However, the patients’ antibody blood tests did not support the diagnosis. When the Mayo Clinic patients discontinued use of olmesartan, the patients gained weight, and their other symptoms disappeared.
In October 2012, researchers at the American College of Gastroenterology meeting said they had seen 40 cases of olmesartan patients who exhibited symptoms suggesting celiac disease.
In its safety announcement, the FDA stated that patients should stop taking olmesartan if they develop diarrhea, vomiting and weight loss and no other cause is found. Sprue-like enteropathy has not been detected with ARB drugs other than olmesartan, the FDA reported.
Compensation for Injuries Due to Benicar
Investigation is needed to determine whether Daiichi Sankyo, the manufacturer of Benicar, understood the drug’s potential side effects prior to putting the medication on the market and whether it sufficiently warned consumers about these side effects.
If you have suffered a severe adverse reaction after using Benicar as prescribed, Will Techmeier of Techmeier Law Firm wants to help you. We have experience working with dangerous drug cases. Our experience provides us with a nationwide network of experts and enables us to deploy the resources required to level the playing field against large drug manufacturers.
Contact a Wisconsin Benicar GI Tract Problem Attorney
Pharmaceutical companies have a lot of money at stake when they produce and market prescription drugs. This makes them aggressive when they have to defend their products against legal claims from people who have suffered drug-related injuries. To succeed against a drug company and its deep resources, you need to work with a law firm that is equally aggressive in protecting your rights.
If you have suffered weight loss due to nausea and diarrhea after taking Benicar or another olmesartan medoxomil prescription drug for high blood pressure, please contact Techmeier Law Firm for a free consultation.
Sources / More Information